Target intelligence / Profile preview

Gastrointestinal adsorptive effect

Molecular classification
Other
01

Overview

The gastrointestinal adsorptive effect describes the mechanism by which certain orally-administered materials (enterosorbents) bind and sequester substances—such as bacterial toxins, bile acids, and sometimes drugs—in the gut, preventing their absorption into the body and promoting their excretion. This effect is non-systemic: the adsorbent agents do not cross the intestinal barrier themselves and are excreted unchanged. The effect is exploited therapeutically in acute poisoning (e.g., activated charcoal), chronic diarrhea, IBS-D, and management of endogenous or exogenous gut-derived toxins. This is not a property of a molecular target such as a receptor, enzyme, or transporter, but rather of the material’s physical-chemical interaction with gut luminal contents. Selection of the adsorbent depends on clinical need (selectivity, safety profile, compatibility with other drugs).

Other names
EnterosorptionIntestinal adsorption effectGastrointestinal adsorption
02

Mechanism of action

Adsorption and sequestration of target substances (toxins, bile acids, drugs) in the GI lumen, thereby preventing their absorption into systemic circulation and facilitating excretion

03

Biological functions

Adsorption of toxinsAdsorption of bacterial productsAdsorption of bile acidsNon-systemic removal of substances from the GI tract
04

Disease associations

Diarrhea (acute and chronic)Irritable bowel syndrome (IBS), especially IBS-DPoisoning (e.g., removal of ingested toxins, drugs)Other (supportive management of gut-derived endotoxemia)
05

Safety considerations

Non-selective adsorption may decrease bioavailability of concomitantly administered drugs and micronutrientsCharcoal and some mineral adsorbents limited to short-term use due to broad binding spectrumPotential for binding essential nutrients with chronic use
06

Interacting drugs

Activated charcoal

3 more in the full profile.

07

Biomarkers

Reduction in stool frequency (clinical outcomes in IBS-D)Stool normalization (Bristol stool scale)Decrease in blood aflatoxin biomarkers (when used for aflatoxin sequestration)

Beyond the preview

Go deeper on Gastrointestinal adsorptive effect.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastrointestinal adsorptive effect.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call